Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - August 29,...
Pharmaceutical
Zomedica’s Assisi Loop(R) Product Line Designated as Fear Free(TM) Preferred Product
Assisi’s tPEMF™ technology aligns with Fear Free’s mission to “prevent and alleviate fear, anxiety, and stress in pets” ANN ARBOR, MI...
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company...
ORYZON to Provide Corporate Progress Updates at Several Events in September
German Fall Conference 2024European College of Neuropsychopharmacology (ECNP) congress 2024Sachs Annual Biotech in Europe Forum 2024 MADRID, Spain and CAMBRIDGE,...
111, Inc. Announces Second Quarter 2024 Unaudited Financial Results
Maintained Operational Profitability for the Second Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoYHeld Positive...
Activation Capital Selects 10 Startups for Inaugural Frontier BioHealth Program
Ten innovative life sciences and healthtech companies enter 16-week accelerator RICHMOND, Va., Aug. 28, 2024 /PRNewswire/ -- Activation Capital, an...
Veeva Announces Fiscal 2025 Second Quarter Results
Total Revenues of $676.2M, up 15% Year Over Year;Subscription Services Revenues of $561.3M, up 19% Year Over Year PLEASANTON, Calif.,...
ClariMed Inc. Expands European Presence with New Office in Leeds, UK
CHADDS FORD, Pa., Aug. 28, 2024 /PRNewswire/ -- ClariMed, Inc., a global leader in human-centered medical device development and regulatory...
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO,...
EydisBio Awarded $2.6 Million Grant to Advance TAK1 Inhibitor Program for Systemic Sclerosis
DURHAM, N.C., Aug. 28, 2024 /PRNewswire/ -- EydisBio, an early-stage pharmaceutical company leveraging a novel approach to treating various autoimmune...
FlackTek™ Technology Reduces Cannabinoid Degradation During Solvent Removal
LANDRUM, S.C., Aug. 28, 2024 /PRNewswire/ -- A pivotal study, "Approaches to Mitigate Cannabinoid Degradation During Solvent Removal," showcases how...
Formedics Acquires AMC Media Group Amplifying Its Content and Peer-to-Peer HCP Community
Formedics—home to flagships Physician's Weekly, Figure 1, and OncWeekly—grows reach by more than 60% to 1.5 million opted-in physicians, nurse...
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
TORONTO, ON / ACCESSWIRE / August 28, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock
BOULDER, CO / ACCESSWIRE / August 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing...
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a company...
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential milestone fees...
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
TORONTO and HAIFA, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the...
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
DOYLESTOWN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage...
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development...
Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF), a clinical-stage biotechnology company...